SELLAS Life Sciences Group, Inc.

📍 New York, United States🗓 Founded 2012👥 26 employees💰 Last funded Feb 2020
Biotechnology Research🌐 sellaslifesciences.com
Website LinkedIn
We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in SELLAS Life Sciences Group, Inc.?
SELLAS Life Sciences Group, Inc. has 1 investors on record on gritt.io and 1 late-stage investors.
When did SELLAS Life Sciences Group, Inc. last raise funding?
The most recent investment in SELLAS Life Sciences Group, Inc. recorded on gritt.io was in February 2020.
When was SELLAS Life Sciences Group, Inc. founded?
SELLAS Life Sciences Group, Inc. was founded in 2012.
What industry is SELLAS Life Sciences Group, Inc. in?
SELLAS Life Sciences Group, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SELLAS Life Sciences Group, Inc. based?
SELLAS Life Sciences Group, Inc. is headquartered in New York, United States.